Transgene Biotek, one of Biotechnology companies in India, announced Monday its novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecutions on the merits have been closed.

This invention by Transgene is targeted for the treatment of hepato-cellular cancer (HCC) based on micro RNA 101 delivered by our novel  and patented Adeno-associated virus 8 serotype (AAV-8).

The company believes that the suppression of EZH2 by  AAV-8-miR-101 is a novel and effective therapeutic approach for the treatment of liver cancer.

Shares of the company gained Rs 0.12, or 4.9%, to trade at Rs 2.57. The total volume of shares traded was 57,768 at the BSE (1.21 p.m., Monday).